Cyclerion Therapeutics, Inc. (CYCN): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYCN POWR Grades
- CYCN scores best on the Sentiment dimension, with a Sentiment rank ahead of 93.54% of US stocks.
- CYCN's strongest trending metric is Value; it's been moving up over the last 148 days.
- CYCN ranks lowest in Momentum; there it ranks in the 12th percentile.
CYCN Stock Summary
- The ratio of debt to operating expenses for Cyclerion Therapeutics Inc is higher than it is for about merely 0.5% of US stocks.
- With a year-over-year growth in debt of -100%, Cyclerion Therapeutics Inc's debt growth rate surpasses only 0% of about US stocks.
- The volatility of Cyclerion Therapeutics Inc's share price is greater than that of 93.5% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to CYCN, based on their financial statements, market capitalization, and price volatility, are CRBP, ONCT, STRO, SLDB, and FDMT.
- Visit CYCN's SEC page to see the company's official filings. To visit the company's web site, go to www.cyclerion.com.
CYCN Valuation Summary
- In comparison to the median Healthcare stock, CYCN's price/earnings ratio is 106.03% lower, now standing at -2.2.
- CYCN's price/earnings ratio has moved down 0.5 over the prior 30 months.
- CYCN's price/earnings ratio has moved down 0.5 over the prior 30 months.
Below are key valuation metrics over time for CYCN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CYCN | 2021-08-31 | 41.2 | 2.3 | -2.2 | -1.2 |
| CYCN | 2021-08-30 | 38.3 | 2.1 | -2.0 | -1.0 |
| CYCN | 2021-08-27 | 39.8 | 2.2 | -2.1 | -1.1 |
| CYCN | 2021-08-26 | 38.3 | 2.1 | -2.0 | -1.0 |
| CYCN | 2021-08-25 | 36.7 | 2.0 | -2.0 | -1.0 |
| CYCN | 2021-08-24 | 36.7 | 2.0 | -2.0 | -1.0 |
CYCN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CYCN has a Quality Grade of C, ranking ahead of 48.21% of graded US stocks.
- CYCN's asset turnover comes in at 0.034 -- ranking 346th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows CYCN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.034 | 1 | -0.991 |
| 2021-03-31 | 0.011 | 1 | -0.741 |
| 2020-12-31 | 0.018 | 1 | -0.770 |
| 2020-09-30 | 0.025 | 1 | -0.733 |
| 2020-06-30 | 0.028 | 1 | -0.734 |
| 2020-03-31 | 0.029 | 1 | -0.788 |
CYCN Price Target
For more insight on analysts targets of CYCN, see our CYCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
CYCN Stock Price Chart Interactive Chart >
CYCN Price/Volume Stats
| Current price | $0.53 | 52-week high | $4.86 |
| Prev. close | $0.58 | 52-week low | $0.50 |
| Day low | $0.52 | Volume | 75,405 |
| Day high | $0.61 | Avg. volume | 138,097 |
| 50-day MA | $0.88 | Dividend yield | N/A |
| 200-day MA | $1.86 | Market Cap | 23.03M |
Cyclerion Therapeutics, Inc. (CYCN) Company Bio
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest CYCN News From Around the Web
Below are the latest news stories about Cyclerion Therapeutics Inc that investors may wish to consider to help them evaluate CYCN as an investment opportunity.
Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
Cyclerion Announces CY6463 Clinical Pipeline and Corporate UpdatesPhase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment Associated with Schizophrenia (CIAS) enrollment ongoing; topline data expected in H2 2022 Phase 2a study in Alzheimer’s Disease with vascular pathology (ADv) enrollment ongoing CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical |
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine CollaborationCollaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairmentCAMBRIDGE, Mass. and PARIS, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and ac |
Stock Of Cyclerion Therapeutics Inc. (NASDAQ: CYCN) Dropped By -15.38 Percent Over The Past Month, Is There Room For Downside?Cyclerion Therapeutics Inc. (NASDAQ:CYCN)s traded shares stood at 0.32 million during the last session. At the close of trading, the stocks price was $1.21, to imply a decrease of -6.92% or -$0.09 in intraday trading. The CYCN shares 52-week high remains $4.86, putting it -301.65% down since that peak but still an impressive 20.66% since Stock Of Cyclerion Therapeutics Inc. (NASDAQ: CYCN) Dropped By -15.38 Percent Over The Past Month, Is There Room For Downside? Read More » |
CENTOGENE Announces Nomination of Andreas Busch to Supervisory BoardNomination adds significant expertise to support pharma partnerships and an impressive track record in value creationCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the nomination of Prof. Andreas Busch as a member of the Supervisory Board, which will be proposed to the shareholders at the next |
CYCN Price Returns
| 1-mo | -35.43% |
| 3-mo | -46.56% |
| 6-mo | N/A |
| 1-year | -82.03% |
| 3-year | -96.50% |
| 5-year | N/A |
| YTD | -69.19% |
| 2021 | -43.79% |
| 2020 | 12.50% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...